证券代码：000534 证券简称：万泽股份 公告编号:2023-050 万泽实业股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会计政策变更概述 1、变更原因 财政部于 2022 年 12 月 13 日发布了《关于印发<企业会计准则解释第 16 号> 的通知》（财会〔2022〕31 号，以下简称"解释第 16 号"），规定 的"关于单项交易产生的资产和负债相关的递延所得税不适用初始确认豁 免的会计处理"的内容自 2023 年 1 月 1 日起施行；规定的"关于发行方 分类为权益工具的金融工具相关股利的所得税影响的会计处理"及"关于 企业将以现金结算的股份支付修改为以权益结算的股份支付的会计处理" 的内容，自公布之日起执行。 根据上述文件的要求，公司对原采用的相关会计政策进行相应变更。 2、变更前采用的会计政策 本次会计政策变更前，公司执行财政部发布的《企业会计准则—基本 准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释 公告以及其他相关规定。 3、变更后采用的会计政策 本次变更后，公司将按照财政部发布的 ...

万泽股份第十一届董事会第二十二次会议资料 万泽实业股份有限公司独立董事 对公司2023年半年报相关事项的独立意见 根据《公司法》和中国证监会相关规范性文件的要求，作为万泽实业 股份有限公司（以下简称"公司"）的独立董事，我们对公司2023年上半 年发生，以及以前期间发生但延续到报告期的关联方资金占用和对外担保 情况进行了认真核查，发表如下专项说明及独立意见： （一）公司不存在报告期内以及以前期间发生但延续到报告期的控股 股东及其他关联方占用公司资金的情形。 （二）截止2023年6月30日，公司对外担保余额为55,768.54万元，占公 司2023年6月30日净资产的42.80%，均是为合并报表范围内子公司提供的担 保。公司不存在报告期内发生或以前期间发生但延续到报告期的为控股股 东及其他关联方、任何法人单位或个人提供担保的情形。 公司对外担保按照有关法律法规、《公司章程》和其他制度规定，履 行了必要的审议程序，没有损害公司及公司股东尤其是中小股东的利益。 2023 年 8 月 18 日 万泽股份第十一届董事会第二十二次会议资料 （此页无正文，仅为公司独立董事对公司2023年半年报相关事项的独立意 见签字页） ...

Revenue and Profitability - Revenue for Q1 2023 reached ¥281,477,110.37, an increase of 106.41% compared to ¥136,369,239.24 in the same period last year[5] - Net profit attributable to shareholders was ¥58,506,301.86, up 79.16% from ¥32,656,024.39 year-on-year[5] - Net profit excluding non-recurring gains and losses increased by 151.60% to ¥54,823,279.11 from ¥21,789,955.27 in the previous year[5] - Basic earnings per share rose to ¥0.1169, reflecting a 78.75% increase from ¥0.0654 in the same period last year[5] - Operating profit for the quarter was ¥70,601,985.59, up 74.4% from ¥40,527,788.99 in Q1 2022[34] - The company reported a total comprehensive income of ¥57,223,058.34 for the quarter, compared to ¥31,528,569.06 in the same period last year, reflecting a growth of 81.7%[35] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,554,560,074.91, a 4.92% increase from ¥2,434,804,891.48 at the end of the previous year[5] - As of March 31, 2023, total assets amounted to RMB 2,554,560,074.91, an increase from RMB 2,434,804,891.48 at the beginning of the year, reflecting a growth of approximately 4.9%[27] - Total liabilities rose to ¥1,219,854,355.07, up from ¥1,194,624,260.30, indicating a growth of 2.1%[31] - Total current liabilities were RMB 601,945,196.31, slightly up from RMB 595,992,771.38, showing a marginal increase of about 1.6%[30] - Long-term borrowings increased to RMB 446,058,788.44 from RMB 428,742,714.26, reflecting a growth of approximately 4%[30] Cash Flow and Investments - Cash flow from operating activities improved significantly, with a net cash outflow of ¥10,190,148.66, a reduction of 88.22% from a net outflow of ¥86,498,490.82 in the previous year[5] - The net cash flow from investment activities was -34,539,552.85, indicating a significant outflow compared to the cash inflow of 409,779.46[39] - The total cash inflow from financing activities was 47,310,000.00, while the cash outflow amounted to 70,548,003.69, resulting in a net cash flow of -23,238,003.69[39] - The cash and cash equivalents at the end of the period were 219,628,670.21, down from 287,675,078.59 at the beginning of the period[39] - The company experienced a negative impact of -78,703.18 from exchange rate fluctuations on cash and cash equivalents[39] Research and Development - Research and development expenses surged by 262.41% compared to the previous year, indicating increased investment in R&D[15] - Research and development expenses for Q1 2023 were ¥15,338,908.50, significantly higher than ¥4,232,434.11 in Q1 2022, marking an increase of 262.5%[33] Stock and Equity - The company plans to grant 8.16 million shares of restricted stock under the 2023 equity incentive plan at a price of RMB 8.58 per share[24] - A total of 1,944,300 stock options were exercised during the first exercise period of the 2020 equity incentive plan, increasing the total share capital by the same amount[23] - The company completed the repurchase and cancellation of 84,000 shares of restricted stock under the 2020 equity incentive plan[23] - Total equity attributable to shareholders increased to ¥1,288,060,805.80, a rise of 8.0% from ¥1,192,252,473.62[31] Other Financial Metrics - The weighted average return on equity increased by 1.77 percentage points to 4.76% from 2.99% year-on-year[5] - Total operating costs for the quarter were ¥209,177,109.93, up 87.0% from ¥111,865,032.88 in the previous year[33] - Accounts receivable increased by 42.96%, primarily due to a significant rise in sales volume of high-temperature alloy products[8] - Contract liabilities rose by 54.75%, mainly due to increased advance payments received by subsidiaries[11] - Inventory levels rose to RMB 138,163,997.25 from RMB 118,834,748.05, indicating an increase of around 16.3%[28] - The company reported a total of 762,498,343.13 in current assets, up from 688,734,739.67 at the beginning of the year, reflecting an increase of approximately 10.7%[28] Audit and Reporting - The company did not conduct an audit for the first quarter report[40] - The report was issued by the board of directors on April 27, 2023, indicating the timeline of the financial disclosure[41]

Financial Performance - The company's operating revenue for 2022 was CNY 793,843,031.64, representing a 20.97% increase compared to CNY 656,255,549.80 in 2021[20]. - The net profit attributable to shareholders of the listed company was CNY 101,719,117.75, a 6.74% increase from CNY 95,292,383.72 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 80,672,086.22, showing a significant increase of 73.55% from CNY 46,484,032.82 in 2021[20]. - The net cash flow from operating activities reached CNY 194,886,261.83, up 42.60% from CNY 136,667,738.73 in the previous year[20]. - The total assets at the end of 2022 were CNY 2,434,804,891.48, reflecting a 14.99% increase from CNY 2,117,454,697.21 at the end of 2021[20]. - The net assets attributable to shareholders of the listed company were CNY 1,192,252,473.62, an increase of 11.30% from CNY 1,071,171,820.88 in 2021[20]. - The basic earnings per share for 2022 were CNY 0.2033, a 5.56% increase from CNY 0.1926 in the previous year[20]. - The diluted earnings per share were CNY 0.2006, up 5.80% from CNY 0.1896 in 2021[20]. - The weighted average return on net assets was 8.87%, a decrease of 0.33 percentage points from 9.20% in the previous year[20]. Revenue Breakdown - Total revenue for the first quarter was ¥136,369,239.24, second quarter ¥238,262,847.19, third quarter ¥206,696,246.69, and fourth quarter ¥212,514,698.52[24]. - The manufacturing sector contributed CNY 180.32 million to total revenue, representing 22.71% of the total, with a significant year-on-year growth of 92.61%[48]. - The pharmaceutical manufacturing sector generated CNY 593.59 million, accounting for 74.77% of total revenue, with a growth of 7.84%[48]. - The southern region accounted for 76.06% of total revenue, with a year-on-year increase of 28.60%[48]. Product Development and R&D - The company completed the R&D of 28 new products, with 8 transitioning to mass production during the reporting period[45]. - The company has applied for a total of 30 invention patents and 25 utility model patents, with 33 patents granted as of December 31, 2022[45]. - The company has achieved an annual production capacity of 10,000 single crystal/directional turbine blade castings, successfully transitioning from research to mass production[43]. - The company has initiated multiple national and provincial-level research projects, including the development of a new generation of high-temperature alloy blades and advanced directional solidification technology[43]. - The company has developed the third-generation powder alloy WZ-A3, which is primarily used in advanced aviation engine turbine discs and other key hot-end components[43]. - The company aims to develop approximately 10 new probiotic strains annually through its probiotic strain library project, which is expected to enhance future product offerings[60]. Marketing and Sales - The company has a nationwide multi-channel marketing system, collaborating with major pharmaceutical groups and over 3,000 hospitals[36]. - The company has established a comprehensive marketing strategy combining brand, academia, and service, and has conducted nearly 2,000 activities under the "365 Public Welfare Plan" by the end of 2022[41]. Cash Flow and Investments - The company reported a net cash outflow from investment activities of ¥386,145,789.65 in 2022, a drastic decline of 406.67% from the previous year's outflow of ¥76,212,993.53[64]. - Total cash inflow from financing activities surged to ¥726,660,498.84 in 2022, marking a 232.81% increase from ¥218,338,581.35 in 2021[65]. - The net increase in cash and cash equivalents was -¥29,024,086.60 in 2022, an improvement of 57.77% from -¥68,734,324.44 in 2021[64]. Shareholder Matters - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares (including tax) to all shareholders[5]. - The total distributable profit for the period is RMB 141,380,759.41, with the cash dividend representing 100% of the total profit distribution[130]. - The cash dividend policy complies with the company's articles of association and has been approved by the board, ensuring transparency and protection of minority shareholders' rights[130][134]. Governance and Compliance - The company actively maintains a governance structure that protects the interests of shareholders, particularly minority shareholders, through a balanced management mechanism[153]. - The company has established a comprehensive internal control system to ensure compliance and asset security, enhancing operational efficiency[144]. - The company reported that 100% of the total assets and operating income of the evaluated units were included in the internal control evaluation scope[146]. Future Outlook - The company anticipates that 2023 will be a year of economic recovery in China, with ongoing structural adjustments in the medical and pharmaceutical sectors[81]. - The high-temperature alloy industry in China is experiencing rapid expansion, driven by advancements in domestic aircraft engine development and increasing localization rates for large aircraft[82]. - In 2023, the company aims to implement its "14th Five-Year Plan" strategy despite a challenging external environment, with a focus on enhancing economic resilience and recovery[82].

证券代码：000534 证券简称：万泽股份 编号：2015-1 万泽实业股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-----------------------------------------------------------|-----------------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 广发基金管理有限公司 严力 | | | 人员姓名 | 长城证券有限责任公司 苏绪盛 广东新价值投资有限公司 冼土权 | 深圳东方平昇投资管理有限公司 张炜兵 深圳市东方港投资管理有限责任公司 于骏晨 | | | | | | | 华夏基金管理公司 | 杨路 | | | 广发证券股份有 ...

证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |----------------|------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ 媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 博时基金管理有限公司 | 田野 | | 人员姓名 | 方正证券股份有限公司 | 杨诚笑 | | | 方正证券股份有限公司 | 孙亮 | | | 方正证券股份有限公司 | 陈文坚 | | | 方正证券股份有限公司 | 蔡靖 | | | 英大证券有限责任公司 | 孙超 | | | 天宏基金管理有限公司 | 田俊维 | | | 东吴基金管理有限公司 | 高人元 | | | 广发证券 赵炳楠 | | | | 广发证券 胡正洋 | | | | ...

证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2016-01 | --- | --- | --- | |----------------|------------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 国信证券股份有限公司 | 詹俊鹏 | | 人员姓名 | 金元证券股份有限公司 | 汪敬波 | | | 海通证券股份有限公司 | 田源 | | | 宝盈基金 陈金伟 | | | | 摩根士丹利华鑫基金 | 朱睿 | | | 摩根士丹利华鑫基金 齐兴芳 | | | | 中银国际证券有限责任公司 | 张铖 | | | 东方证券 姚婕 | | | | 平安资产管理有限责任公司 | 马克明 | | | 天弘基金管理有限公司 | 李佳 ...

证券代码：000534 证券简称：万泽股份 万泽实业股份有限公司 投资者关系活动记录表 编号：2019-01 | --- | --- | --- | |----------------|-------------------------|---------------------------------| | | | | | 投资者关系活动 | ■ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 安信证券 冯福章、张傲 | | | 人员姓名 | 国泰基金 高亮 | | | | 泰信基金 刘杰 | | | | 中庚基金 季国峰 | | | | 高毅资产 庞韬 | | | | 华泰柏瑞基金 | 孙婕衎 | | | 交银基金 郭若 | | | | 鼎萨资产 陈峰 | | | | 上海军民融合基金 | 赵大地 | | | 翌沛投资 陈钢 | | | 时间 | 2019 年 9 月 24 | 日下午 | 1 | --- | --- | ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥206,696,246.69, representing a year-over-year increase of 9.21%[5]. - Net profit attributable to shareholders for the same period was ¥21,041,930.49, a slight increase of 0.06% compared to the previous year[5]. - The net profit excluding non-recurring gains and losses reached ¥15,996,767.42, up 12.53% year-over-year[5]. - Total operating revenue for the third quarter reached ¥581,328,333.12, an increase of 23.9% compared to ¥469,317,731.14 in the same period last year[63]. - Net profit for the period was ¥98,557,830.45, representing a 25% increase from ¥78,947,152.15 in the previous year[66]. - Total comprehensive income amounted to ¥98,557,830.45, an increase from ¥78,947,152.15 in the previous period[70]. - Net income attributable to the parent company was ¥95,584,195.05, up from ¥85,149,613.97 year-over-year[70]. - Basic earnings per share increased to ¥0.1922 from ¥0.1731, while diluted earnings per share rose to ¥0.1894 from ¥0.1719[70]. Cash Flow and Liquidity - Cash flow from operating activities showed a significant decline, with a net amount of ¥21,593,345.37, down 71.21% compared to the same period last year[5]. - Cash inflows from operating activities totaled ¥592,602,213.29, compared to ¥541,529,840.89 in the prior period[73]. - Net cash flow from operating activities decreased to ¥21,593,345.37 from ¥74,991,746.44 year-over-year[73]. - Cash outflows from investing activities were ¥294,869,102.15, down from ¥372,849,337.86 in the previous period[77]. - Net cash flow from investing activities was -¥293,521,368.04, worsening from -¥144,599,504.44 year-over-year[77]. - Cash inflows from financing activities increased to ¥299,660,498.84 from ¥134,670,541.37[77]. - Net cash flow from financing activities improved to ¥114,130,554.11 from -¥155,768,603.56 year-over-year[77]. - The ending balance of cash and cash equivalents was ¥159,226,199.00, slightly down from ¥159,749,222.35 in the previous period[79]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,307,440,965.43, an increase of 8.97% from the end of the previous year[5]. - The company's total assets increased to ¥2,307,440,965.43, compared to ¥2,117,454,697.21, marking a growth of 9%[58]. - The total liabilities increased to ¥1,084,532,061.66, up from ¥1,017,964,343.14, reflecting a growth of 6.5%[58]. - The total current assets decreased to ¥611,263,227.36 as of September 30, 2022, from ¥663,389,003.51 on January 1, 2022, representing a decline of approximately 7.9%[50]. Equity and Shareholder Information - The total equity attributable to shareholders increased by 10.19% to ¥1,180,289,800.48 compared to the end of the previous year[5]. - The equity attributable to shareholders of the parent company increased to ¥1,180,289,800.48 from ¥1,071,171,820.88, reflecting a growth of 10.2%[58]. - The company approved adjustments to the exercise price of stock options under the 2020 equity incentive plan from ¥13.64 per share to ¥13.59 per share[45]. - The company granted 4.995 million restricted shares under the 2021 equity incentive plan at a price of ¥7.70 per share[46]. - The company plans to adjust the repurchase price of restricted shares under the 2021 equity incentive plan from ¥7.70 per share to ¥7.65 per share[46]. - A total of 927,900 restricted shares were released for trading on April 19, 2022, following the completion of the first unlock period[40]. - The company has not disclosed any known relationships among the top shareholders or whether they are acting in concert as defined by the regulations[36]. Research and Development - The company's R&D expenditure increased by 173.87% compared to the beginning of the period, reflecting a stronger focus on innovation[17]. - Research and development expenses decreased to ¥45,627,246.42 from ¥49,068,106.23, a reduction of 7.4%[63]. Accounts Receivable and Inventory - The number of accounts receivable increased by 91.84%, primarily due to a significant rise in sales volume of high-temperature alloy products[13]. - Accounts receivable increased to ¥247,461,479.88 as of September 30, 2022, compared to ¥128,991,111.94 on January 1, 2022, reflecting a growth of approximately 92.1%[50]. - Inventory as of September 30, 2022, was ¥128,683,745.13, up from ¥102,004,036.62 on January 1, 2022, indicating an increase of about 26.1%[50]. Operating Costs - The company reported a 39.70% increase in operating costs year-over-year, attributed to higher sales volumes[25]. - Total operating costs amounted to ¥470,320,849.76, up from ¥437,482,348.27, reflecting a year-over-year increase of 7.6%[63]. Other Information - The company experienced a 100% decrease in non-current assets due within one year, mainly due to the repayment of financing lease loans[12]. - The company has not reported any significant new product developments or market expansions in the recent quarter[39]. - Long-term equity investments rose to ¥9,527,587.54 from ¥9,168,917.89, indicating a year-over-year increase of 3.9%[58]. - The company reported a significant increase in contract liabilities, which rose to ¥4,162,548.20 from ¥2,395,039.87, a growth of 74%[56].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥374,632,086.43, representing a 33.78% increase compared to ¥280,044,176.91 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was ¥74,542,264.56, up 16.25% from ¥64,119,929.34 year-on-year[26]. - The net profit after deducting non-recurring gains and losses was ¥62,012,240.94, a significant increase of 178.46% compared to ¥22,269,365.88 in the previous year[26]. - Basic earnings per share were ¥0.1496, up 15.25% from ¥0.1298 in the same period last year[26]. - The diluted earnings per share were ¥0.1474, an increase of 14.35% compared to ¥0.1289 in the previous year[26]. - The weighted average return on net assets was 6.71%, an increase of 0.46 percentage points from 6.25% in the previous year[26]. Cash Flow and Assets - The net cash flow from operating activities was -¥22,416,225.97, a decrease of 173.08% from ¥30,674,776.38 in the same period last year[26]. - The total assets at the end of the reporting period were ¥2,369,267,045.73, an increase of 11.89% from ¥2,117,454,697.21 at the end of the previous year[26]. - The net assets attributable to shareholders of the listed company were ¥1,143,727,378.04, reflecting a 6.77% increase from ¥1,071,171,820.88 at the end of the previous year[26]. - Cash and cash equivalents decreased to ¥310,951,206.87, accounting for 13.12% of total assets, down 2.03 percentage points from the previous year[65]. - Accounts receivable increased to ¥207,972,861.13, representing 8.78% of total assets, up 2.69 percentage points due to revenue growth[65]. - Inventory rose to ¥128,777,525.77, making up 5.44% of total assets, an increase of 0.62 percentage points[65]. - Short-term borrowings increased to ¥205,474,510.55, which is 8.67% of total assets, up 1.51 percentage points due to increased funding needs from business growth[65]. - Long-term borrowings rose to ¥349,968,890.39, accounting for 14.77% of total assets, an increase of 2.00 percentage points[65]. Business Operations and Growth - The main business of the company includes the research, production, and sales of micro-ecological live bacteria products and high-temperature alloys[37]. - The company achieved a 50% growth in the clinical market for its product "Dingjunsheng" during the reporting period[39]. - The company has launched a new product, "Wanze Shuangqi Three-Component Probiotic Powder," in July 2022, expanding its product line in the health food sector[41]. - The company has completed the construction of its Zhuhai base and Shenzhen Wanze Microbiology Research Institute, with plans for formal operation by the end of 2022[41]. - The company has a production capacity of 100 pieces/year for powder discs, 100 tons/year for powder, and 60 tons/year for master alloys at its Shen-Shan facility[44]. - The company has initiated over 20 projects in high-temperature alloy blade technology, with 15 projects completed and over 2,000 finished products delivered during the reporting period[43]. - The company has established a comprehensive marketing system covering prescription drugs, OTC products, and health foods, collaborating with over 3,000 hospitals and 100,000 pharmacies nationwide[47]. - The company is focused on expanding its market presence and enhancing its research capabilities in the probiotic field through strategic partnerships[39]. Research and Development - The company's research and development expenses amounted to ¥58,234,709.45, which is a 21.70% increase from the previous year[56]. - The company has established a complete R&D and testing system for high-temperature alloys, achieving several key technological breakthroughs and obtaining multiple patents[49]. - The company has formed stable long-term partnerships with several domestic research institutions and enterprises in the high-temperature alloy field[49]. Financial Management and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[6]. - The company held three temporary shareholder meetings in 2022, with investor participation rates of 46.63%, 46.60%, and 46.36% respectively[86]. - The total number of shares increased from 495,713,096 to 500,623,096 due to stock incentives[145]. - The total number of common shareholders at the end of the reporting period was 19,610, with the largest shareholder, Wanze Group Co., Ltd., holding 39.47% of shares, equating to 197,608,136 shares[159]. - The company’s stock incentive plans are aimed at aligning the interests of management and shareholders[153]. Environmental and Regulatory Compliance - The company has not faced any administrative penalties related to environmental issues during the reporting period[101]. - The company is not classified as a key pollutant discharge unit by environmental protection authorities[102]. - The company has established a comprehensive internal control system to protect the interests of shareholders, especially minority shareholders, by implementing a management mechanism that balances the powers of the shareholders' meeting, board of directors, and supervisory board[103]. Miscellaneous - The company did not experience any changes in its controlling shareholder or actual controller during the reporting period[165]. - There were no significant litigation or arbitration matters during the reporting period[114]. - The half-year financial report has not been audited[110].